Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo

International Immunopharmacology

Volumn 4, Issue 1, 2004, Pages 15-24

  Denkinger, Michael ^a,b   Shive, Carey L ^a   Pantenburg, Birte ^a   Forsthuber, Thomas G ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adjuvants; Cytokines; Immunomodulators; Th1 Th2

Indexed keywords

ALUMINUM FLUORIDE; ALUMINUM HYDROXIDE; BENZALKONIUM CHLORIDE; COMPOUND 48-80; EGG WHITE; FREUND ADJUVANT; GUANINE NUCLEOTIDE BINDING PROTEIN; HEN EGGWHITE LYSOZYME; IMMUNOLOGICAL ADJUVANT; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NF 023; PERTUSSIS TOXIN; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; SURAMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEN; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

EID: 1242306567     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2003.09.004     Document Type: Article

References (39)

1. Cunha-Neto E. MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Braz. J. Med. Biol. Res. 32(2):1999;199-205.
2. Janeway C.A.J. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 1):1989;1-13.
3. Yip H.C., Karulin A.Y., Tary-Lehmann M.et al. Adjuvant-guided type-1 and type-2 Immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162(7):1999;3942-3949.
4. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:1994;991-1045.
5. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
6. Ryan M., McCarthy L., Rappuoli R., Mahon B.P., Mills K.H. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int. Immunol. 10(5):1998;651-662.
7. Fearon D.T., Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science. 272(5258):1996;50-53.
8. Lafferty K.J., Cunningham A.J. A new analysis of allogeneic interactions. Aust. J. Exp. Biol. Med. Sci. 53(1):1975;27-42.
9. Mosman T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145.
10. Janeway C.A.J. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today. 13:1992;11-16.
11. Medzhitov R., Preston-Hurlburt P., Janeway C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. [see comments] Nature. 388(6640):1997;394-397.
12. Vabulas R.M., Ahmad-Nejadm P., da Costa C.et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem. 276(33):2001;31332-31339.
13. Kol A., Lichtman A.H., Finberg R.W., Libby P., Kurt-Jones E.A. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J. Immunol. 164(1):2000;13-17.
14. Schnurr M., Then F., Galambos P.et al. Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. J. Immunol. 165(8):2000;4704-4709.
15. Warny M., Aboudola S., Robson S.C.et al. P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. J. Biol. Chem. 276(28):2001;26051-26056.
16. Shive C.L., Hofstetter H., Arredondo L., Shaw C., Forsthuber T.G. The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells. Eur. J. Immunol. 30(8):2000;2422-2431.
17. Agren L.C., Ekman L., Lowenadler B., Nedrud J.G., Lycke N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162(4):1999;2432-2440.
18. Valujskikh A., Matesic D., Gilliam A., Anthony D., Haqqi T.M., Heeger P.S. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice. J. Clin. Invest. 101(6):1998;1398-1407.
19. Valujskikh A., Matesic D., Heeger P.S. Characterization and manipulation of T cell immunity to skin grafts expressing a transgenic minor antigen. Transplantation. 68(7):1999;1029-1036.
20. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358(6382):1992;155-157.
21. Karulin A.Y., Hesse M.D., Tary-Lehmann M., Lehmann P.V. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J. Immunol. 164(4):2000;1862-1872.
22. Ries J., Stein J., Traynor-Kaplan A.E., Barrett K.E. Dual role for AlF4(-)-sensitive G proteins in the function of T84 epithelial cells: transport and barrier effects. Am. J. Physiol. 272(3 Pt 1):1997;C794-C803.
23. Rapuano B.E., Bockman R.S. Pertussis toxin-sensitive and insensitive G proteins mediate ALFL4-stimulated release of inositol phosphates, diglycerides and arachidonic acid in MC3T3-E1 osteoblasts. Prostaglandins Leukot. Essent. Fatty Acids. 50(4):1994;177-181.
24. Chabre M. Aluminofluoride and beryllofluoride complexes: a new phosphate analogs in enzymology. Trends Biochem. Sci. 15(1):1990;6-10.
25. Tomita U., Inanobe A., Kobayashi I., Takahashi K., Ui M., Katada T. Direct interactions of mastoparan and compound 48/80 with GTP-binding proteins. J. Biochem. (Tokyo). 109(1):1991;184-189.
26. Chahdi A., Fraundorfer P.F., Beaven M.A. Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins. J. Pharmacol. Exp. Ther. 292(1):2000;122-130.
27. Freissmuth M., Boehm S., Beindl W.et al. Suramin analogues as subtype-selective G protein inhibitors. Mol. Pharmacol. 49(4):1996;602-611.
28. Freissmuth M., Waldhoer M., Bofill-Cardona E., Nanoff C. G protein antagonists. Trends Pharmacol. Sci. 20(6):1999;237-245.
29. Patarca R., Rosenzwei J.A., Zuniga A.A., Fletcher M.A. Benzalkonium salts: effects on G protein-mediated processes and surface membranes. Crit. Rev. Oncog. 11(3-4):2000;255-305.
30. Beindl W., Mitterauer T., Hohenegger M., Ijzerman A.P., Nanoff C., Freissmuth M. Inhibition of receptor/G protein coupling by suramin analogues. Mol. Pharmacol. 50(2):1996;415-423.
31. Middaugh C.R., Mach H., Burke C.J.et al. Nature of the interaction of growth factors with suramin. Biochemistry. 31(37):1992;9016-9024.
32. Dunn P.M., Blakeley A.G. Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br. J. Pharmacol. 93(2):1988;243-245.
33. Ziyal R., Ziganshin A.U., Nickel P.et al. Vasoconstrictor responses via P2X-receptors are selectively antagonized by NF023 in rabbit isolated aorta and saphenous artery. Br. J. Pharmacol. 120(5):1997;954-960.
34. Mahoney C.W., Azzi A., Huang K.P. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J. Biol. Chem. 265(10):1990;5424-5428.
35. Braun M.C., Kelsall B.L. Regulation of interleukin-12 production by G-protein-coupled receptors. Microbes. Infect. 3(2):2001;99-107.
36. Toshkov A., Neychev H., Dimov V. Suramin increases the nonspecific antibacterial resistance through macrophage activation. Acta Microbiol. Bulg. 19:1986;13-17.
37. Ko H.L., Beuth J., Tunggal L., Gil M., Jeljaszewicz J., Pulverer G. Enhancement of immune responses to suramin correlates with antineoplastic activity in BALB/c-mice. In Vivo. 8(2):1994;173-176.
38. Brandely M., Lagrange P.H., Hurtrel B. Effects of suramin on the in vivo antimicrobial resistance against Listeria monocytogenes and Mycobacterium bovis (BCG) in mice. Clin. Exp. Immunol. 63(1):1986;118-126.
39. Voogd T.E., Vansterkenburg E.L., Wilting J., Janssen L.H. Recent research on the biological activity of suramin. Pharmacol. Rev. 45(2):1993;177-203.